Please login to the form below

Not currently logged in
Email:
Password:

ASH meeting

This page shows the latest ASH meeting news and features for those working in and with pharma, biotech and healthcare.

FDA clears first-line use for J&J’s myeloma drug Darzalex

FDA clears first-line use for J&J’s myeloma drug Darzalex

The approval is based on the results of the ALCYONE clinical trial presented at the American Society of Haematology (ASH) meeting last December which showed that adding Darzalex to VMP cut

Latest news

  • BCMA in the spotlight as ASH abstracts drop BCMA in the spotlight as ASH abstracts drop

    BCMA in the spotlight as ASH abstracts drop. Updated results from promising CAR-T therapies are expected. ... Drugs which target the BCMA receptor look set to feature prominently at this year’s American Society of Haematology (ASH) meeting, with new

  • Celgene to launch five new products through to 2020 Celgene to launch five new products through to 2020

    The late-stage pipeline is setting Celgene up for a busy American Society of Haematology (ASH) meeting in December, with new data expected on both CAR-T therapies as well as ... We look forward to reporting on and realizing the benefits of several

  • Geron poleaxed as partner J&J abandons only pipeline drug Geron poleaxed as partner J&J abandons only pipeline drug

    A lot will rest on data from the two trials that Geron hopes to present at the American Society of Haematology (ASH) meeting in November.

  • Spark sputters on haemophilia A gene therapy safety scare Spark sputters on haemophilia A gene therapy safety scare

    Haematologists will get a chance to sift through the data in full after it’presented at the American Society of Haematology (ASH) meeting in December. ... meeting the factor threshold because of reactions – suggesting that could affect SPK-8011’s

  • AbbVie, Roche get FDA OK for broader use of Venclexta AbbVie, Roche get FDA OK for broader use of Venclexta

    of Haematology (ASH) meeting. ... The trial was the first to test new a new CLL agent against standard chemo-immunotherapy and – according to investigators at ASH – suggested that Venclexta should replace chemotherapy in relapsed or

More from news
Approximately 4 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    This is despite some positive news for Juno released at the recent ASH meeting that another of its CAR T cell therapeutics, JCAR017, showed a 60% complete response in patients with ... As Juno wrestles with bad publicity and a depressed share price,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics